BioSpace News Archive

Medtronic plc (NYSE:MDT), the global leader in medical technology, today introduced the MiniMed™ Mio™ Advance infusion set to all Medtronic insulin pump customers in the United States. The MiniMed Mio Advance infusion set is the newest addition to the MiniMed™ portfolio of infusion sets and gives people using insulin pumps an optimal user experience with fewer steps 1 . The MiniMed Mio Advance infusion set is inserted in only four steps — individ

The data has been submitted to the EPA for review to include claims of disinfection against the virus on the label

EHO360 is an experienced national Hospice Pharmacy Benefit Manager with a deep understanding of the hospice system with hospice provider clients across the country.

Syntellis Performance Solutions, a leading provider of enterprise performance management software, data and analytics solutions for healthcare, higher education and financial institutions, today announced the launch of its Advantage Program,

BIOASIS TECHNOLOGIES INC. announced that it has granted stock options to acquire a total of 1,495,000 common shares effective June 30, 2020 at a price of $0.31 per share to directors and officers of the company.

Quantum Leap Healthcare Collaborative™ announced the initiation of an investigational treatment arm with Byondis’ [vic-]trastuzumab duocarmazine in the ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.

The assay is intended to aid in the diagnosis of and identification of carriers for spinal muscular atrophy (SMA)

The healthcare industry is moving with a massive pace towards transformation.

Studies show the small molecule adjuvant significantly increases IgG binding antibody responses Company establishes scalable manufacturing supply chain to meet pandemic demands HOUSTON, July 07, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases, announced today that preclinical studies reveal 7HP349, an oral integrin activator that promotes cell adhesion, si

NEW HAVEN, Conn., July 07, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting platform, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding its proposed IND and Phase I/II study for its lead candidate, CBX-12 (alphalex™-exatecan). Cybrexa plans to submit the IND application for CBX